Trial reportDrug design, development and therapy2025
Comparing Liposomal Bupivacaine and Ropivacaine in Serratus Anterior Plane Block for Thoracoscopic Lobectomy: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Modified Single-Side-Lying Quadratus Lumborum Block Combined with Liposomal Bupivacaine versus Transversus Abdominis Plane Block for Post-Cesarean Analgesia: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Liposomal Bupivacaine versus Bupivacaine with Dexamethasone for Rhomboid Intercostal and Sub-Serratus Block in Thoracoscopic Lobectomy: A Randomized Controlled Trial.Journal of pain research · 2026Trial
- Liposomal Bupivacaine for Adductor Canal Block Combined with IPACK Block in Total Knee Arthroplasty: A Prospective, Double-Blind, Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- The Analgesic Efficacy of Liposomal Bupivacaine in Adductor Canal Block Following Knee Arthroplasty: A Single-Center, Prospective, Randomized and Controlled Clinical Trial.Drug design, development and therapy · 2025Trial
- Liposomal Bupivacaine Versus Ropivacaine in Combined Thoracic Paravertebral Block and Serratus Anterior Plane Block for Thoracoscopic Surgery: A Randomized Controlled Trial.The Kaohsiung journal of medical sciences · 2026Article
- Article
- Liposomal bupivacaine for postoperative analgesia after thoracoscopic surgery: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Liposomal Bupivacaine for Serratus Anterior Plane Block in Modified Radical Mastectomy: Protocol for a Randomized, Double-Blind Trial Evaluating Pain-Related and Early Recovery Outcomes.Journal of pain research · 2026Article
- Efficacy of repetitive transcranial magnetic stimulation on postoperative pain in patients undergoing video-assisted thoracoscopic surgery: study protocol for a prospective, single-center, randomized controlled trial.Frontiers in medicine · 2026Article
- Effect of Liposomal Bupivacaine in Peripheral Nerve Block Following Thoracoscopic Lung Surgery: A Systematic Review and Meta-Analysis.Journal of pain research · 2026Review
- Liposomal bupivacaine in thoracic surgery: a comprehensive review of current evidence and clinical implications.Frontiers in medicine · 2026Review
- The Efficacy and Safety of Serratus Anterior Plane Block for Pain Management in Patients with Rib Fractures: a Narrative Review.Current pain and headache reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: The optimal analgesic regimen after video-assisted thoracoscopic surgery (VATS) is unclear. We aimed to examine whether ultrasound-guided serratus anterior plane block (SAPB) with liposomal bupivacaine could provide continuous and effective analgesic effects for lung cancer patients undergoing VATS. Methods: A total of 64 patients were randomly allocated to receive either the liposomal bupivacaine (LB group) or the ropivacaine (RO group). The primary outcome was pain score at rest and on movement in the first three days after surgery. The secondary outcomes included intraoperative remifentanil consumption, perioperative consumption of sufentanil and flurbiprofen axetil, time to extubation, time to first bowel movement, time to first flatus, incidence of postoperative nausea and vomiting (PONV), length of intensive care unit (ICU) stay, length of hospital stay, hospitalization costs, and early recovery quality as assessed by QoR-15 score. Results: The LB group had significantly lower pain scores at rest and on movement at 12h, 24h, 36h, 48h, and 72h after surgery, and lower pain scores on movement at 8h after surgery, when compared with the RO group. Perioperative sufentanil consumption and postoperative flurbiprofen axetil consumption were significantly reduced in the LB group than in the RO group. In addition, compared with the RO group, the LB group had earlier first flatus, mobilization, and urinary catheter removal, shorter ICU stay, lower incidence of PONV, and lower hospitalization costs. The QoR-15 scores in the first three days after surgery were significantly higher in the LB group than in the RO group. There were no statistically significant differences between the two groups regarding time to extubation, intraoperative remifentanil consumption, and length of hospital stay. Conclusion: Ultrasound-guided SAPB with liposomal bupivacaine was effective in relieving postoperative pain for three days after surgery in patients undergoing VATS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.